NASDAQ$IOVA
Iovance Biotherapeutics Inc. · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported third quarter and year-to-date financial results and corporate updates.
Iovance Biotherapeutics reported a net loss of $86.1 million, or $0.55 per share, for the third quarter ended September 30, 2021. The company had $660.8 million in cash, cash equivalents, investments and restricted cash at September 30, 2021. They are focused on addressing FDA feedback regarding potency assays for lifileucel to support their planned BLA submission.
- Continued to report long-term clinical data demonstrating the durability of one-time treatment with lifileucel in metastatic melanoma.
- Broadened the potential for TIL cell therapy to address more patients in additional indications and treatment settings.
- Top priority remains ongoing work to address FDA feedback regarding potency assays for lifileucel to support planned BLA submission.
- The company had $660.8 million in cash, cash equivalents, investments and restricted cash at September 30, 2021.
Headline financials
Revenue & EPS history
Iovance · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-1.0%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-1.2%
Avg return
30 days after
37%
20 / 54 earnings
Positive
+36.3%
Q4 2019
Best reaction
-45.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -13.2% | -12.7% | +3.4% | |
| Q4 2025 | +30.1% | +33.6% | +27.7% | |
| Q3 2025 | +27.9% | +46.4% | +21.5% | |
| Q1 2025 | -45.1% | -46.1% | -35.3% | |
| Q4 2024 | -19.4% | -23.0% | -32.3% | |
| Q3 2024 | -12.8% | -20.2% | -25.6% | |
| Q2 2024 | +35.3% | +46.5% | +36.6% | |
| Q1 2024 | -18.1% | -19.9% | -41.9% | |
| Q4 2023 | -8.9% | +72.3% | +67.9% | |
| Q3 2023 | -3.5% | -8.1% | +55.8% | |
| Q2 2023 | +7.8% | +0.1% | -17.7% | |
| Q1 2023 | +7.9% | +5.5% | +13.0% | |
| Q4 2022 | +1.8% | +2.5% | -14.2% | |
| Q3 2022 | +0.0% | -7.0% | -23.1% | |
| Q2 2022 | +1.2% | -0.2% | -8.8% | |
| Q1 2022 | -12.4% | -17.2% | -52.4% | |
| Q4 2021 | +10.2% | +9.4% | +20.5% | |
| Q3 2021 | +0.6% | -0.2% | -33.4% | |
| Q2 2021 | +3.2% | +2.1% | +10.1% | |
| Q1 2021 | -2.4% | -9.3% | -38.7% | |
| Q4 2020 | -5.4% | -5.3% | -27.3% | |
| Q3 2020 | +2.2% | -3.7% | +8.9% | |
| Q2 2020 | -5.3% | -8.8% | -0.7% | |
| Q1 2020 | +1.2% | +12.0% | -4.3% | |
| Q4 2019 | +36.3% | +33.3% | +29.4% | |
| Q3 2019 | -0.7% | +7.5% | +12.5% | |
| Q2 2019 | -3.5% | -8.6% | -14.6% | |
| Q1 2019 | -5.5% | -3.2% | +61.2% | |
| Q4 2018 | -1.7% | +7.8% | -9.0% | |
| Q3 2018 | -3.2% | -5.1% | +5.3% | |
| Q2 2018 | +6.9% | +6.5% | +23.3% | |
| Q1 2018 | +0.7% | +1.0% | -16.2% | |
| Q4 2017 | -8.6% | -11.8% | -21.2% | |
| Q3 2017 | -6.5% | +2.0% | +18.3% | |
| Q2 2017 | -5.1% | -4.3% | -1.7% | |
| Q1 2017 | -9.8% | -11.7% | -24.8% | |
| Q4 2016 | -1.3% | +2.7% | -10.1% | |
| Q3 2016 | +5.1% | +19.7% | +2.6% | |
| Q2 2016 | -2.1% | -1.5% | -11.1% | |
| Q1 2016 | +4.4% | — | — | |
| Q4 2015 | -5.4% | — | — | |
| Q3 2015 | — | — | — | |
| Q4 2014 | +18.7% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q2 2013 | -2.8% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -20.0% | — | — | |
| Q2 2012 | -26.0% | — | — | |
| Q1 2012 | +2.6% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | -0.8% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +6.1% | — | — | |
| Q4 2010 | +0.0% | — | — | |
| Q3 2010 | -4.5% | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro